The World Health Organization (WHO) hopes to publish complete data on trials of the AZD1222 coronavirus vaccine, developed by the British-Swedish company AstraZeneca and the University of Oxford. This was reported on Saturday, November 28, by RIA Novosti .
“We have heard from AstraZeneca that they want to conduct a full trial of low doses of the vaccine to better understand the higher efficacy of low doses. This will be welcome as the current trials are examining the full dose,” the WHO said, noting that, only by studying the detailed data will they be able to better understand the effectiveness of the vaccine.
The organization stressed that the information published by the developers in a recent press release is insufficient, and it is too early to comment on them.
On November 23, the developer of the AZD1222 vaccine stated that it showed average efficiency in 70 percent. During the tests, two variants of drug administration were tested. In the first case, more than 2.7 thousand people of AZD1222 were administered first in a half dose, and a month later in full, and the effectiveness was 90 percent. The variant with the introduction of two full doses with a difference of a month was tested on 9 thousand people, and the result was only 62 percent.